X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

PAREXEL Co-Founder and Board Chairman Josef von Rickenbach Receives 2018 Ellis Island Medal of Honor

Content Team by Content Team
15th May 2018
in Americas, News

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, announced that Josef von Rickenbach, PAREXEL co-founder and Chairman of the Board of Directors, is the recipient of a 2018 Ellis Island Medal of Honor from the Ellis Island Honors Society (EIHS). Mr. von Rickenbach was honored with the recognition at a ceremony on Ellis Island on May 12.

The Ellis Island Medals of Honor are presented annually to a select group of individuals whose accomplishments in their field and inspired service to our nation are cause for celebration. The honor recognizes individuals who have made it their mission to share their wealth of knowledge, indomitable courage, boundless compassion, unique talents and selfless generosity with those less fortunate. The Medal has been officially recognized by both Houses of Congress as one of our nation’s most prestigious awards and is annually memorialized in the Congressional Record. Past Ellis Island Medal of Honor recipients include seven Presidents of the United States, Vice-President Joe Biden, Supreme Court Justice Sandra Day O’Connor and several Nobel laureates.

“I have always had a strong belief in both the great opportunities that exist in America, and the need to understand and respect the global environment in which we live and work. As such, I am deeply honored to receive an Ellis Island Medal of Honor from the Ellis Island Honors Society,” Mr. von Rickenbach said. “This prestigious recognition symbolizes the great diversity, integrity, passion and courage of America, all fundamental values that PAREXEL was built on, and I am truly humbled to be recognized among this remarkable list of honorees.”

A native of Switzerland, Mr. von Rickenbach co-founded PAREXEL in 1982 and retired as CEO earlier this year. During his tenure, he led the company’s approximately 18,000 employees to meaningfully contribute to 99 percent of the 200 top-selling biopharmaceuticals in the world today, products that help address patient needs in oncology, neurology, infectious disease, and countless other disease conditions. Mr. von Rickenbach became a U.S. citizen in 2002.

“Now more than ever it’s vital we recognize, celebrate, and embrace the diversity and backgrounds of all of the Americans who enrich and build upon the foundation of this great country,” said Nasser J. Kazeminy, Chairman of EIHS. “At the Ellis Island Honors Society, we want to focus on the future by honoring our past and present and with the Ellis Island Medals of Honor, we’re recognizing leaders and everyday heroes who are making a positive impact in order to build a better, brighter future for all Americans.”

In addition to the Ellis Island Medal of Honor, Mr. von Rickenbach was recently recognized by Informa’s Pharma Intelligence, receiving the Lifetime Achievement Award at the Clinical and Research Excellence Awards. He was also an Honoree at the Evening of Hope event benefitting the Biomedical Science Careers Program (BSCP), a non-profit organization that provides students of every race, ethnic background, gender and financial status with encouragement, support and guidance needed for the successful pursuit of biomedical science and other science-related careers.

About PAREXEL International
PAREXEL International Corporation is the world’s leading innovator of biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit www.PAREXEL.com.

Previous Post

Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition

Next Post

HDA's Pharmaceutical Cargo Security Coalition Recognizes Leaders for Commitment to a Safe and Secure Supply Chain

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post

HDA's Pharmaceutical Cargo Security Coalition Recognizes Leaders for Commitment to a Safe and Secure Supply Chain

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In